HER2-targeted antibody-drug conjugate

HER2-targeted antibody-drug conjugates (ADCs) represent a sophisticated class of oncology therapeutics designed to deliver cytotoxic agents directly to cells expressing the Human Epidermal Growth Factor Receptor 2 (HER2). This specific entry refers to the class of anti-HER2 ADCs being investigated by the Tianjin Medical University Cancer Institute and Hospital, particularly in the context of a Phase 2 clinical trial (NCT06143306) evaluating the correlation between serum HER2 levels and drug efficacy in patients with HER2-low expressing breast cancer. These ADCs, which include agents like trastuzumab deruxtecan (T-DXd), utilize a monoclonal antibody to target HER2-positive or HER2-low cells, followed by internalization and release of a potent payload to induce cell death. The research at Tianjin aims to validate serum HER2 as a dynamic biomarker for monitoring treatment response and optimizing drug selection in the breast cancer setting.

Other names

anti-HER2-ADCanti-HER-2-ADCanti-HER 2-ADCHER2-ADCHER-2-ADCHER 2-ADCAgainst HER 2-ADC DrugHER2-ADC-Tianjin Medical University Cancer Institute and Hospital-Breast cancerHER-2-ADC-Tianjin Medical University Cancer Institute and Hospital-Breast cancerHER 2-ADC-Tianjin Medical University Cancer Institute and Hospital-Breast cancer